Report Buyer, the online destination for business intelligence, has added a new report showing that growth in the use of cardiovascular drugs has been steady in the last five years at around three percent compound annual growth rate (CAGR) and growth is expected to continue at a similar rate, in-line with population growth.
Commercial Insight: Cardiovascular market overview reports that despite growth in the use of cardiovascular drugs, sales growth is unlikely to match this. Growth in the last five years has been moderate at eight percent CAGR but there is likely to be negligible growth between now and 2016, giving an effective fall of three percent in cardiovascular revenues.
Continue reading “Cardiovascular Drug Blockbusters Under Pressure From Raft of Patent Expiries” »
